Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
| 대상 질환 | Glioma, Glioblastoma |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Wake Forest University Health Sciences |
| 상태 | 조기 종료 |
| 참여자 수 | 2 명 |
| 중재(약물) | Soliramfetol |
| 시작일 | 2021년 1월 27일 |
| 완료일 | 2021년 11월 22일 |
| 결과 공개일 | 2025년 10월 21일 |
요약
This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors (gliomas).
Proportion With Grade 3 or Higher Adverse Events
| Solriamfetol | 0 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed M — National Cancer Institute (NCI)